MDxHealth Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Mike McGarrity

Chief Executive Officer (CEO)

US$571.1k

Compensación total

Porcentaje del salario del CEO	78.8%
Permanencia del CEO	4.8yrs
Participación del CEO	n/a
Permanencia media de la dirección	4.7yrs
Promedio de permanencia en la Junta Directiva	6yrs

Actualizaciones recientes de la dirección

Recent updates

Why Investors Shouldn't Be Surprised By MDxHealth SA's (EBR:MDXH) 29% Share Price Plunge

Oct 05

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Mike McGarrity en comparación con los beneficios de MDxHealth?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2023	n/a	n/a	-US$45m
Jun 30 2023	n/a	n/a	-US$48m
Mar 31 2023	n/a	n/a	-US$47m
Dec 31 2022	US$571k	US$450k	-US$44m
Sep 30 2022	n/a	n/a	-US$40m
Jun 30 2022	n/a	n/a	-US$34m
Mar 31 2022	n/a	n/a	-US$31m
Dec 31 2021	US$540k	US$386k	-US$29m
Sep 30 2021	n/a	n/a	-US$28m
Jun 30 2021	n/a	n/a	-US$28m
Mar 31 2021	n/a	n/a	-US$28m
Dec 31 2020	US$582k	US$452k	-US$29m
Sep 30 2020	n/a	n/a	-US$36m
Jun 30 2020	n/a	n/a	-US$43m
Mar 31 2020	n/a	n/a	-US$43m
Dec 31 2019	US$442k	US$347k	-US$43m

Compensación vs. Mercado: La compensación total ($USD571.15K) de Mike está en línea con el promedio de empresas de tamaño similar en el mercado Belgian ($USD469.24K).

Compensación vs. Ingresos: La compensación de Mike ha aumentado mientras la empresa no es rentable.

CEO

Mike McGarrity (60 yo)

4.8yrs

Permanencia

US$571,149

Compensación

Mr. Michael K. McGarrity, also known as Mike, has been the Chief Executive Officer and Executive Director at MDxHealth SA since February 18, 2019. Mr. McGarrity has experience in the healthcare industry wi...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Michael McGarrity	CEO & Executive Director	4.8yrs	US$571.15k	sin datos
Ron Kalfus	Chief Financial Officer	4.4yrs	sin datos	0% $ 0
Joseph Sollee	Executive VP of Corporate Development & General Counsel	no data	sin datos	0% $ 0
John Bellano	Chief Commercial Officer	4.5yrs	sin datos	0% $ 0
Miriam Reyes	Executive Vice President of Operations	4.9yrs	sin datos	sin datos
Wim Van Criekinge	Chief Scientific Officer	no data	sin datos	sin datos

4.7yrs

Permanencia media

52.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de MDXH se considera experimentado (4.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Michael McGarrity	CEO & Executive Director	4.8yrs	US$571.15k	sin datos
Donnie Hardison	Independent Non-Executive Director	2.3yrs	US$76.03k	sin datos
Hilde Windels	Independent Non-Executive Director	6.2yrs	US$49.26k	0% $ 0
Jan Pensaert	Non-Executive Director	9.6yrs	US$10.71k	0% $ 0
Jan Groen	Advisor to the Board	4.8yrs	US$798.45k	sin datos
James Herman	Member of Scientific Advisory Board	no data	sin datos	sin datos
Gerrit Meijer	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jonathan Epstein	Member of Scientific Advisory Board	12.8yrs	sin datos	sin datos
Eric Wallen	Member of Scientific Advisory Board	12.8yrs	sin datos	sin datos
Regine Slagmulder	Independent Non-Executive Director	3.3yrs	US$63.18k	0.22% $ 178.2k
Koen Hoffman	Independent Non-Executive Chairman	5.9yrs	US$109.22k	0% $ 0
Godelieve Verplancke	Independent Non-Executive Director	6.3yrs	US$55.68k	0% $ 0

6.0yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: La junta directiva de MDXH se considera experimentada (6 años de antigüedad promedio).

MDxHealth Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

MDxHealth SA Announces Jan Pensaert Steps Down from its Board of Directors

Mdxhealth Sa Announces Resignation of Rudi Mariën as Non-Executive Director

Recent updates

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering

MDxHealth SA Maintains Earnings Guidance for the Year 2024

MDxHealth SA Announces Jan Pensaert Steps Down from its Board of Directors

MDxHealth SA Provides Earnings Guidance for the Fourth Quarter and Full Year 2023 and Year 2024

MDxHealth SA to Report Q1, 2024 Results on May 08, 2024

MDxHealth SA Shares No Longer Be Listed and Traded on Euronext Brussels, Effective as of Close of Trading on Euronext Brussels on December 15, 2023

MDxHealth SA Shares No Longer Be Listed and Traded on Euronext Brussels, Effective as of Close of Trading on Euronext Brussels on December 15, 2023

New minor risk - Profitability

MDxHealth SA Provides Earnings Guidance for the Year 2023

MDxHealth SA Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Why Investors Shouldn't Be Surprised By MDxHealth SA's (EBR:MDXH) 29% Share Price Plunge

MDxHealth SA to Report Q3, 2023 Results on Oct 09, 2023

Consensus EPS estimates fall by 10%, revenue upgraded

MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?

New major risk - Share price stability

MDxHealth SA Reaffirms Revenue Guidance for the Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

MDxHealth (EBR:MDXH) Is Carrying A Fair Bit Of Debt

Full year 2022 earnings released: US$0.28 loss per share (vs US$0.24 loss in FY 2021)

Third quarter 2022 earnings released: US$0.078 loss per share (vs US$0.06 loss in 3Q 2021)

MDxHealth SA to Report First Half, 2023 Results on Aug 23, 2023

MDxHealth SA Provides Revenue Guidance for the Fiscal Year 2023

MDxHealth SA Revises Revenue Guidance for the Fiscal Year 2022

Price target increased to €1.20

MDxHealth SA Reaffirms Revenue Guidance for the Year 2022

Third quarter 2022 earnings released: US$0.05 loss per share (vs US$0.059 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.072 loss per share (vs US$0.06 loss in 2Q 2021)

MDxHealth SA (ENXTBR:MDXH) acquired Oncotype DX GPS Prostate Cancer Business from Exact Sciences Corporation (NasdaqCM:EXAS) for $100 million.

MDxHealth SA (ENXTBR:MDXH) acquired Oncotype DX GPS Prostate Cancer Business from Exact Sciences Corporation (NasdaqCM:EXAS) for $100 million.

Mdxhealth Sa Announces Resignation of Rudi Mariën as Non-Executive Director

Palmetto GBA’s MolDX Issues Foundational LCD Covering the Indication for SelectMDx for Prostate Cancer

Is MDxHealth (EBR:MDXH) Using Debt In A Risky Way?

Full year 2021 earnings released

Price target increased to €1.20

MDxHealth SA Provides Revenue Guidance for the Full Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Here's Why MDxHealth (EBR:MDXH) Can Manage Its Debt Despite Losing Money

First half 2021 earnings released: US$0.12 loss per share (vs US$0.18 loss in 1H 2020)

MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?

Full year 2020 earnings released: US$0.34 loss per share (vs US$0.69 loss in FY 2019)

Revenue misses expectations

MDxHealth SA to Report Fiscal Year 2020 Results on Apr 28, 2021

MDxHealth SA to Report Fiscal Year 2020 Results on Mar 03, 2021

MDxHealth SA to Report First Half, 2021 Results on Aug 26, 2021

New 90-day high: €1.07

MDxHealth's (EBR:MDXH) Stock Price Has Reduced 75% In The Past Five Years

New 90-day high: €1.00

Is MDxHealth (EBR:MDXH) Weighed On By Its Debt Load?

Price target raised to €1.00

MDxHealth SA Suspends 2020 Guidance

New 90-day low - €0.69

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad